Virax Biolabs Faces NASDAQ Minimum Bid Price Deficiency Notice
Virax Biolabs Faces NASDAQ Notice
Virax Biolabs Group Limited (NASDAQ: VRAX) is in the spotlight following the receipt of a notification letter from the NASDAQ stock market. This letter, dated July 14, 2025, indicates that the company has failed to comply with the minimum bid price requirement set forth by NASDAQ Listing Rule 5550(a)(2). Under this rule, listed securities are required to maintain a minimum bid price of $1.00 per share. If this deficiency continues for thirty consecutive business days, a notice is issued. Virax’s situation now puts the company in a precarious position as it navigates compliance protocols.
The minimum bid price rule is critical for companies listed on NASDAQ as it ensures that shares remain viable and are actively traded. The notification does not lead to immediate delisting; however, it sets a clock ticking for Virax Biolabs. The company has been given a compliance period of 180 calendar days to remedy this issue, which extends until January 12, 2026. To regain compliance, Virax must ensure that the closing bid price of its ordinary shares stays above $1.00 for at least ten consecutive business days.
In the event that they are unable to achieve this by the conclusion of the compliance period, Virax may eligible for an additional grace period of another 180 days. Notification from NASDAQ does not equate to a delisting at this time, and trading of Virax shares under the ticker